Background: Snoring and OSA is very commonly seen among the pediatric population, most commonly due to adenoid and tonsil hypertrophy which requires adenotonsillectomy. The effect of this surgery on the immunity is controversial. This study was planned to see any alternative therapy which can delay or avoid the surgery by providing symptomatic relief to the patient.
INTRODUCTION
Adenoid hypertrophy is known to be associated with several harmful clinical conditions 1,2 which range from mild nasal obstruction, otitis media to severe obstructive sleep apnea syndrome (OSAS). Delayed diagnosis and treatment of these diseases may result in consequences such as behavior alterations, low growth and weight gain, craniofacial alterations secondary to mouth breathing, mastication and swallowing disorders, in addition to cor pulmonale and left heart failure. 3 OSAS in children is usually managed with adenotonsillectomy which needs general anesthesia and sometimes is associated with complications. As adjunctive treatments, medical methods for reduction of adenoid size are limited. However, recent studies showed that topical nasal corticosteroid spray reduced adenoid size and improved symptoms of nasal airway obstruction and OSAS. 4 The clinical data in Indian population is still limited hence this present study is planned to see the clinical effi cacy of mometasone on patients with adenoid hypertrophy. 4 Sunder Singh than 25 were considered as obese. After the enrolment, the children were put on the intranasal mometasone therapy. The outcome of intranasal mometasone was done using the same OSA18 questionnaire after the period of 4 weeks.
MATERIALS AND METHODS
The OSA-18, is a valid and reliable discriminative quality of life (QOL) measure for children with varying levels of sleep disabled breathing. 5 The survey consists of 18 items grouped into 5 domains: sleep disturbance (4 items), physical suffering (4 items), emotional distress (3 items), daytime problems (3 items), and caregiver concerns (4 items). Items are scored on a 7-point ordinal scale and have excellent test-retest reliability.
STATISTICAL ANALYSIS
All the data assembled was presented as mean ± standard deviation. Results were analyzed with the help of appropriate parametric (two tailed student's t-test) test. A p < 0.05 was considered as statistically signifi cant.
RESULTS
All the 55 patients enrolled in the study completed the study. Table 1 presents the general information of all the 55 patients who took part in the study. Intranasal mometasone was given in 55 patients for 4 weeks. All the patients completed the trail with minimal side effects like dry mouth and epistaxis. Three patients reported minimal epistaxis, which got controlled without any medical aid. Parents of 3 patients who were less than 6 years of age had some diffi culty using nasal steroids as their child was not cooperative. Table 2 shows the changes of OSA 18 survey score before and after treatment. The average total score showed improvement from 56.33 to 51.51 which is signifi cant (p < 0.001). There is signifi cant improvement in all the fi ve domins of OSA 18 score (Graph 1). All the parents reported that there was signifi cant improvement in the sleep and snoring, and is evident by reduction in scores 3.29 to 2.93 and 3.11 to 2.93 respectively. With the treatment of intranasal mometasone the problem of rhinorrhea also improved markedly (p < 0.001) with average score of 2.91.
Among the 55 patients 21 patients showed allergic features, with the intranasal therapy the allergic symptoms also subsided but the allergy had no affect on the effi cacy of intranasal mometasone. Ten patients were found to have obesity. However, there was no change in body mass index after the treatment and there was signifi cant improvement in both obese and nonobese patients.
DISCUSSION
The palatine and pharyngeal tonsils, along with the lingual and tubal tonsils and the lateral pharyngeal bands are the important structures of Waldeyer's ring. They are secondary lymphoid organs, part of the mucosa-associated lymphoid tissue (MALT), which present immune activity mainly between 4 and 10 years of age. 6 Adenoidal hypertrophy is most common cause of obstructive sleep apnea and the cardiopulmonary syndrome, as severe complication. Adenoidal hypertrophy is one of the most frequent indications for surgery in childhood, and adenoidectomy commonly is considered definitive treatment for nasopharyngeal obstruction. 7 Although adenotonsillectomy is the most commonly performed procedure in children, its true impact upon the pediatric immune system is controversial. 8 Encouraging results concerning chronic obstructive nasal symptoms due to adenoid in pediatric population were reported by use of intranasal steroid for short period. In order to see any alternative modality which can prevent or delay the requirement of adenoidectomy, we evaluated the utility of mometasone furoate aqueous nasal spray in children with adenoidal hypertrophy. Chadha and Zhang 9 reviewed seven studies including a total of 493 patients and found six of these studies demonstrated signifi cant effi cacy of various nasal steroids (mometasone, beclomethasone, fl unisolide) in improving nasal obstruction symptoms and in reducing adenoid size, as measured with symptom scores and fi ber-optic nasopharyngeal endoscopy, respectively. The response appeared to be a group effect and may be maintained longerterm by continuing nasal steroids at a lower maintenance dose. The treatment was safe and well-tolerated with few minor adverse events. In the present study we used the mometasone nasal spray as the data on Indian population is limited. We used OSA 18 questionnaire in order to evaluate the effects of mometasone which is a standard protocol for quality of life evaluation in cases of obstructive sleep apnea due to adenoids. Berlucchi and Valetti 10 evaluated the utility of mometasone furoate aqueous nasal spray in children with adenoidal hypertrophy in long-term maintenance therapy. Their study describes the long-term follow-up of children undergoing mometasone furoate aqueous nasal spray treatment for adenoidal hypertrophy. Voluntary suspension of maintenance therapy favors surgery of this disorder, whereas its regular administration may lead to successful results. In the present study short term use of intranasal mometasone has shown to decrease the adenoid size and symptom improvement. Rezende 11 used the mometasone with saline irrigation and found the combination useful, but in the present study the intranasal mometasone alone was found to be suffi cient for improvement. Intranasal mometasone has no effect on the tonsillar hypertrophy in the present study. Several mechanisms, such as direct lymphocytic action, inhibition of infl ammation, and alteration of adenoid bacterial fl ora, have been suggested to explain how steroids decrease adenoid pad volume and improve symptoms of adenoidal hypertrophy, although none has yet achieved widespread acceptance. 
CONCLUSION
The available evidence suggests that short term use of nasal steroids may signifi cantly improve nasal obstruction symptoms in children with adenoid hypertrophy. This improvement appears to be associated with a reduction of adenoid size. Evidence of long-term effi cacy is awaited. Further studies are required to support the use of nasal steroids as a fi rst-line approach in these children. 
